

Graham R Foster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4169305/publications.pdf>

Version: 2024-02-01

231
papers

18,108
citations

22099

59
h-index

13727

129
g-index

285
all docs

285
docs citations

285
times ranked

17682
citing authors

#	ARTICLE	IF	CITATIONS
1	Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2014, 370, 1889-1898.	13.9	1,580
2	Telaprevir for Retreatment of HCV Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2417-2428.	13.9	1,466
3	Interferons at age 50: past, current and future impact on biomedicine. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 975-990.	21.5	970
4	Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2608-2617.	13.9	740
5	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet, The</i> , 2014, 384, 1953-1997.	6.3	492
6	Increase in primary liver cancer in the UK, 1979-1994. <i>Lancet, The</i> , 1997, 350, 1142-1143.	6.3	490
7	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. <i>Hepatology</i> , 2013, 58, 1598-1609.	3.6	431
8	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2014, 384, 403-413.	6.3	431
9	Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2016, 64, 1224-1231.	1.8	425
10	Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. <i>Hepatology</i> , 2002, 35, 433-439.	3.6	407
11	Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	13.9	361
12	Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 741-747.	1.8	351
13	Evidence for a cerebral effect of the hepatitis C virus. <i>Lancet, The</i> , 2001, 358, 38-39.	6.3	316
14	Combination of Tenofovir Disoproxil Fumarate and Peginterferon α -2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 134-144.e10.	0.6	284
15	The way forward in HCV treatment - finding the right path. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 991-1000.	21.5	267
16	Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1. <i>New England Journal of Medicine</i> , 2014, 370, 222-232.	13.9	262
17	Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B. <i>Gastroenterology</i> , 2012, 143, 637-645.	0.6	257
18	Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study. <i>BMJ Open</i> , 2020, 10, e043828.	0.8	233

#	ARTICLE	IF	CITATIONS
19	Dengue Virus Inhibits Alpha Interferon Signaling by Reducing STAT2 Expression. <i>Journal of Virology</i> , 2005, 79, 5414-5420.	1.5	227
20	Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. <i>Gastroenterology</i> , 2014, 146, 430-441.e6.	0.6	217
21	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	0.6	215
22	Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection. <i>Gastroenterology</i> , 2015, 149, 1462-1470.	0.6	214
23	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. <i>Journal of Hepatology</i> , 2011, 54, 1137-1144.	1.8	199
24	Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. <i>Journal of Hepatology</i> , 2012, 57, 1379-1390.	1.8	194
25	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. <i>Hepatology</i> , 2012, 55, 49-57.	3.6	194
26	Characterization of \hat{I}^2 -R1, a Gene That Is Selectively Induced by Interferon \hat{I}^2 (IFN- \hat{I}^2) Compared with IFN- \hat{I}^1 . <i>Journal of Biological Chemistry</i> , 1996, 271, 22878-22884.	1.6	168
27	Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. <i>Journal of Clinical Investigation</i> , 2018, 128, 668-681.	3.9	167
28	Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections. <i>Gastroenterology</i> , 2011, 141, 881-889.e1.	0.6	164
29	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, 533-540.	1.8	161
30	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. <i>Journal of Hepatology</i> , 2016, 65, 17-25.	1.8	157
31	Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. <i>Journal of Medical Virology</i> , 2003, 71, 49-55.	2.5	152
32	Pharmacology and therapeutic potential of interferons. , 2012, 135, 44-53.		143
33	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet</i> , The, 2018, 391, 1097-1107.	6.3	140
34	Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. <i>Nature Genetics</i> , 2017, 49, 666-673.	9.4	129
35	Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133.	3.7	128
36	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1 patients without cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 293-300.	1.8	127

#	ARTICLE	IF	CITATIONS
37	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. Scientific Reports, 2016, 6, 25487.	1.6	125
38	Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucleic Acids Research, 1991, 19, 4387-4393.	6.5	119
39	The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology, 2012, 55, 749-758.	3.6	108
40	Telomere Erosion in Memory T Cells Induced by Telomerase Inhibition at the Site of Antigenic Challenge In Vivo. Journal of Experimental Medicine, 2004, 199, 1433-1443.	4.2	107
41	Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. The Lancet Gastroenterology and Hepatology, 2018, 3, 626-634.	3.7	103
42	Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. Journal of Hepatology, 2013, 58, 792-800.	1.8	100
43	Type I interferons and the innate immune response—more than just antiviral cytokines. Molecular Immunology, 2005, 42, 869-877.	1.0	99
44	Pegylated interferons: chemical and clinical differences. Alimentary Pharmacology and Therapeutics, 2004, 20, 825-830.	1.9	97
45	Pegylated Interferons for the Treatment of Chronic Hepatitis C. Drugs, 2010, 70, 147-165.	4.9	91
46	Quality of life considerations for patients with chronic hepatitis C. Journal of Viral Hepatitis, 2009, 16, 605-611.	1.0	90
47	Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology, 1999, 117, 1187-1197.	0.6	86
48	Chronic Exposure to Helicobacter pylori Impairs Dendritic Cell Function and Inhibits Th1 Development. Infection and Immunity, 2007, 75, 810-819.	1.0	85
49	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. Journal of Hepatology, 2016, 64, 234-238.	1.8	85
50	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clinical Infectious Diseases, 2016, 63, 1479-1481.	2.9	81
51	Herpes Simplex Virus Type-1-Induced Activation of Myeloid Dendritic Cells: The Roles of Virus Cell Interaction and Paracrine Type I IFN Secretion. Journal of Immunology, 2004, 173, 4108-4119.	0.4	79
52	Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood, 2010, 116, 2875-2883.	0.6	79
53	Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. European Journal of Public Health, 2012, 22, 187-192.	0.1	79
54	Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut, 2012, 61, 128-134.	6.1	76

#	ARTICLE	IF	CITATIONS
55	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2015, 386, 2098-2111.	6.3	76
56	Assessment of Bone Mineral Density in Tenofovir-Treated Patients With Chronic Hepatitis B: Can the Fracture Risk Assessment Tool Identify Those at Greatest Risk?. <i>Journal of Infectious Diseases</i> , 2015, 211, 374-382.	1.9	75
57	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	2.4	72
58	IFN- γ Subtypes Differentially Affect Human T Cell Motility. <i>Journal of Immunology</i> , 2004, 173, 1663-1670.	0.4	68
59	Mechanisms of action of interferon and nucleoside analogues. <i>Journal of Hepatology</i> , 2003, 39, 93-98.	1.8	63
60	Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. <i>Psychoneuroendocrinology</i> , 2019, 100, 276-285.	1.3	62
61	Past, Present, and Future Hepatitis C Treatments. <i>Seminars in Liver Disease</i> , 2004, 24, 97-104.	1.8	60
62	Hepatitis C virus therapy to date. <i>Antiviral Therapy</i> , 2008, 13, 3-8.	0.6	60
63	The $\text{C}^{\text{M}}\text{ag}$ Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices. <i>Artificial Organs</i> , 2015, 39, 93-101.	1.0	59
64	Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. <i>Journal of Hepatology</i> , 2015, 62, 41-47.	1.8	59
65	<i>Cryptosporidium parvum</i> Infection Rapidly Induces a Protective Innate Immune Response Involving Type I Interferon. <i>Journal of Infectious Diseases</i> , 2009, 200, 1548-1555.	1.9	56
66	Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1042-1048.	2.9	56
67	Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. <i>Gut</i> , 2017, 66, 519-529.	6.1	54
68	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
69	Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. <i>PLoS Pathogens</i> , 2016, 12, e1005788.	2.1	54
70	Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. <i>Lancet, The</i> , 2020, 395, 226-239.	6.3	53
71	Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 883-889.	1.8	52
72	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. <i>Journal of Hepatology</i> , 2015, 63, 1086-1092.	1.8	49

#	ARTICLE	IF	CITATIONS
73	Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 247-255.	0.6	48
74	Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. <i>Immunology</i> , 2005, 116, 245-254.	2.0	47
75	Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 688-693.	2.4	47
76	Interferons in Host Defense. <i>Seminars in Liver Disease</i> , 1997, 17, 287-295.	1.8	46
77	Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. <i>Hepatology</i> , 2015, 62, 1013-1023.	3.6	46
78	Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention. <i>BMC Medicine</i> , 2019, 17, 71.	2.3	46
79	The Effect of Shear Stress on the Size, Structure, and Function of Human von Willebrand Factor. <i>Artificial Organs</i> , 2014, 38, 741-750.	1.0	45
80	Human Type I Interferons Differ Greatly in Their Effects on the Proliferation of Primary B Cells. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 309-318.	0.5	44
81	An orally available, small-molecule interferon inhibits viral replication. <i>Scientific Reports</i> , 2012, 2, 259.	1.6	42
82	Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. <i>BMC Public Health</i> , 2015, 15, 151.	1.2	42
83	Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. <i>Annals of Surgery</i> , 2016, 263, 1028-1037.	2.1	41
84	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1&6 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , 2018, 38, 443-450.	1.9	40
85	Ethnicity and the diagnosis gap in liver disease: a population-based study. <i>British Journal of General Practice</i> , 2014, 64, e694-e702.	0.7	39
86	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004, 40, 478-483.	1.8	38
87	Prevalence of Hepatitis C-Related Cirrhosis in Elderly Asian Patients Infected in Childhood. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 910-917.	2.4	37
88	Randomised controlled trial of GP-led in-hospital management of homeless people (â€ˆPathwayâ€™™). <i>Clinical Medicine</i> , 2016, 16, 223-229.	0.8	36
89	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy001.	0.4	36
90	Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8656-8661.	3.3	35

#	ARTICLE	IF	CITATIONS
91	Second generation direct-acting antivirals “ Do we expect major improvements?. Journal of Hepatology, 2016, 65, S130-S142.	1.8	35
92	New metrics for the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2017, 389, 2053-2080.	6.3	33
93	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction, 2019, 114, 1113-1122.	1.7	33
94	Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug and Alcohol Dependence, 2019, 194, 487-494.	1.6	33
95	Directed evolution of gene-shuffled IFN- λ molecules with activity profiles tailored for treatment of chronic viral diseases. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8269-8274.	3.3	32
96	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. Journal of Clinical Virology, 2017, 92, 32-38.	1.6	32
97	Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. Journal of Hepatology, 2017, 67, 1348-1350.	1.8	31
98	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) “ a natural experiment (protocol). BMJ Open, 2019, 9, e029538.	0.8	30
99	Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals. BMC Health Services Research, 2015, 15, 97.	0.9	29
100	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS ONE, 2019, 14, e0208506.	1.1	29
101	Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scandinavian Journal of Gastroenterology, 2006, 41, 577-585.	0.6	28
102	Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therapeutic Advances in Gastroenterology, 2012, 5, 139-151.	1.4	28
103	Managing Diabetes in Patients with Chronic Liver Disease. Postgraduate Medicine, 2012, 124, 130-137.	0.9	28
104	Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy, 2017, 47, 230-238.	1.6	28
105	Interferon lambda 4 impacts the genetic diversity of hepatitis C virus. ELife, 2019, 8, .	2.8	28
106	Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology, 2019, 157, 692-704.e9.	0.6	27
107	Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. Journal of Hepatology, 2001, 35, 512-516.	1.8	26
108	Expression of the terminal protein of hepatitis B virus is associated with failure to respond to interferon therapy. Hepatology, 1993, 17, 757-762.	3.6	25

#	ARTICLE	IF	CITATIONS
109	Global hepatitis, migration and its impact on Western healthcare. <i>Gut</i> , 2010, 59, 1009-1011.	6.1	24
110	Diagnosis and treatment of chronic hepatitis B. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 318-321.	1.1	23
111	Modeling the impact of early antiretroviral therapy for adults coinfecting with HIV and hepatitis B or C in South Africa. <i>Aids</i> , 2014, 28, S35-S46.	1.0	23
112	Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. <i>Frontline Gastroenterology</i> , 2018, 9, 115-121.	0.9	23
113	Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. <i>Journal of Infection</i> , 2019, 79, 503-512.	1.7	23
114	Serum F protein: A new sensitive and specific test of hepatocellular damage. <i>Clinica Chimica Acta</i> , 1989, 184, 85-92.	0.5	22
115	Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2015, 62, 294-302.	1.8	22
116	Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 805-813.	3.7	22
117	Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. <i>Hepatology</i> , 2018, 67, 2113-2126.	3.6	22
118	Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 32-44.	3.7	22
119	The relationship of histology to genotype in chronic HCV infection. <i>Liver</i> , 1997, 17, 144-151.	0.1	21
120	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. <i>Hepatology</i> , 2013, 58, 1897-1906.	3.6	21
121	The Evaluation of Leukocytes in Response to the In Vitro Testing of Ventricular Assist Devices. <i>Artificial Organs</i> , 2013, 37, 793-801.	1.0	21
122	SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. <i>Journal of Medical Virology</i> , 2017, 89, 1620-1628.	2.5	21
123	Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. <i>Clinical Infectious Diseases</i> , 2018, 66, 1742-1750.	2.9	21
124	Sofosbuvir and Velpatasvir for Patients with HCV Infection. <i>New England Journal of Medicine</i> , 2016, 374, 1687-1689.	13.9	20
125	The association between hepatocellular carcinoma and direct-acting antiviral treatment in patients with decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 204-214.	1.9	20
126	Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?. <i>Addiction</i> , 2008, 103, 1412-1413.	1.7	19

#	ARTICLE	IF	CITATIONS
127	Endothelin-1 as a Mediator and Potential Biomarker for Interferon Induced Pulmonary Toxicity. <i>Pulmonary Circulation</i> , 2012, 2, 501-504.	0.8	19
128	Reevaluation of the Harboe Assay as a Standardized Method of Assessment for the Hemolytic Performance of Ventricular Assist Devices. <i>Artificial Organs</i> , 2012, 36, 724-730.	1.0	19
129	Sustained virologic response rates with telaprevir by response after 4weeks of lead-in therapy in patients with prior treatment failure. <i>Journal of Hepatology</i> , 2013, 58, 488-494.	1.8	19
130	STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2015, 62, 1246-1255.	1.8	19
131	Hepatitis C virus therapy to date. <i>Antiviral Therapy</i> , 2008, 13 Suppl 1, 3-8.	0.6	19
132	Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 685-691.	0.9	18
133	Prevalence and Risk Factors of Asymptomatic Hepatitis C Virus Infection in Bangladesh. <i>Journal of Clinical and Experimental Hepatology</i> , 2011, 1, 13-16.	0.4	18
134	Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 1182-1188.	1.4	18
135	New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. <i>Lancet, The</i> , 2021, 397, 1770-1780.	6.3	18
136	Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. <i>Journal of Gastroenterology</i> , 2019, 54, 752-761.	2.3	17
137	High yield expression, refolding, and characterization of recombinant interferon β hybrids in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2003, 31, 222-230.	0.6	16
138	Diagnosis and Treatment of Chronic Hepatitis B. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 318-321.	1.1	16
139	Response to antiviral therapy in patients with genotype 3 chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 747-753.	0.8	16
140	HCV genotype-3a T cell immunity: specificity, function and impact of therapy. <i>Gut</i> , 2012, 61, 1589-1599.	6.1	15
141	Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. <i>Journal of Viral Hepatitis</i> , 2013, 20, e115-23.	1.0	15
142	Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: Final results from the STEPS trial. <i>Journal of Hepatology</i> , 2014, 60, 699-705.	1.8	15
143	Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis. <i>Liver International</i> , 2016, 36, 145-150.	1.9	15
144	Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?. <i>BMJ Open</i> , 2016, 6, e010661.	0.8	14

#	ARTICLE	IF	CITATIONS
145	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 177-186.	1.6	13
146	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. <i>Value in Health</i> , 2019, 22, 693-703.	0.1	13
147	Diagnosis and Treatment of Hepatitis C. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 223-225.	1.1	12
148	Advances in the diagnosis and treatment of hepatitis B. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 508-515.	1.3	12
149	Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost. <i>Journal of Translational Medicine</i> , 2022, 20, 2.	1.8	12
150	Diagnosis and treatment of hepatitis C. <i>Journal of the Royal Society of Medicine</i> , 2004, 97, 223-225.	1.1	11
151	IFN- λ 2 Induces Leukocyte Integrin Redistribution, Increased Adhesion, and Migration. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 291-304.	0.5	11
152	Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 471-485.	1.0	11
153	The prevalence of hepatitis C virus among people of South Asian origin in Glasgow – Results from a community based survey and laboratory surveillance. <i>Travel Medicine and Infectious Disease</i> , 2013, 11, 301-309.	1.5	11
154	IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. <i>SpringerPlus</i> , 2016, 5, 1990.	1.2	11
155	Quantification methods for human and large animal leukocytes using DNA dyes by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 565-574.	1.1	11
156	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	1.8	11
157	Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. <i>Hepatology International</i> , 2018, 12, 17-25.	1.9	11
158	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. <i>Nature Communications</i> , 2021, 12, 6105.	5.8	11
159	Activity of Hybrid Type I Interferons in Cells Lacking Tyk2: A Common Region of IFN- λ 8 Induces a Response, but IFN- λ 2/8 Hybrids Can Behave Like IFN- λ 2. <i>Journal of Interferon and Cytokine Research</i> , 2003, 23, 655-666.	0.5	10
160	Influencing Factors on the Outcome and Prognosis of Patients With HBV Infection: Seven Years Follow-up. <i>Hepatitis Monthly</i> , 2013, 13, e8743.	0.1	10
161	World Gastroenterology Organisation Global Guidelines. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 204-217.	1.1	10
162	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180mg and uprifosbuvir 450mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	1.0	10

#	ARTICLE	IF	CITATIONS
163	Disparities of SARS-CoV-2 Nucleoprotein-Specific IgG in Healthcare Workers in East London, UK. <i>Frontiers in Medicine</i> , 2021, 8, 642723.	1.2	10
164	A cross sectional study of colonic diverticulosis in the London Bangladeshi population. <i>United European Gastroenterology Journal</i> , 2013, 1, 191-197.	1.6	8
165	A randomized, controlled study of peginterferon lambda-1a/ribavirin±Aadaclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
166	Third-generation ventricular assist devices. , 2018, , 151-186.		8
167	English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 168-181.	1.9	8
168	Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. <i>Eurosurveillance</i> , 2019, 24, .	3.9	8
169	Role of peer support in a hepatitis C elimination programme. <i>Journal of Viral Hepatitis</i> , 2022, 29, 43-51.	1.0	8
170	Reversible AIDS-related sclerosing cholangitis. <i>Journal of Hepatology</i> , 1995, 23, 209-211.	1.8	7
171	Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1258-1263.	0.8	7
172	Recent advances in viral hepatitis. <i>Clinical Medicine</i> , 2009, 9, 613-616.	0.8	6
173	Randomized clinical trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 543-550.	0.8	6
174	Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. <i>Liver International</i> , 2015, 35, 448-454.	1.9	6
175	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	1.3	6
176	Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. <i>PLoS ONE</i> , 2017, 12, e0168713.	1.1	6
177	Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. <i>Annals of Gastroenterology</i> , 2017, 30, 327-343.	0.4	6
178	DIFFERENT ACTIVITIES OF TYPE I INTERFERONS ON HEPATITIS B VIRUS CORE PROMOTER REGULATED TRANSCRIPTION. <i>Cytokine</i> , 2002, 17, 214-220.	1.4	5
179	Development of a radial ventricular assist device using numerical predictions and experimental haemolysis. <i>Medical Engineering and Physics</i> , 2013, 35, 1197-1203.	0.8	5
180	Development and validation of a capture-fusion model to study drug sensitivity of patient-derived hepatitis C. <i>Hepatology</i> , 2015, 61, 1192-1204.	3.6	5

#	ARTICLE	IF	CITATIONS
181	Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. <i>PLoS ONE</i> , 2016, 11, e0151703.	1.1	5
182	Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study. <i>Infectious Diseases and Therapy</i> , 2017, 6, 265-275.	1.8	5
183	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy248.	0.4	5
184	Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study. <i>Heliyon</i> , 2020, 6, e04534.	1.4	5
185	Improving care transfers for homeless patients after hospital discharge: a realist evaluation. <i>Health Services and Delivery Research</i> , 2021, 9, 1-186.	1.4	5
186	Selection of HCV NS5A quasispecies during IFN therapy in patients with chronic HCV. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1399-1408.	1.1	4
187	Apoptotic cell death: the caspase-cleavage "gold rush". <i>Lancet, The</i> , 2005, 365, 1293-1294.	6.3	4
188	Shorter treatments for hepatitis C: another step forward?. <i>Lancet, The</i> , 2015, 385, 1054-1055.	6.3	4
189	Chronic hepatitis C: less of a problem than first thought?. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 146-147.	3.7	4
190	An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). <i>PLoS ONE</i> , 2016, 11, e0158526.	1.1	4
191	Chronic hepatitis B virus monoinfection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , 2018, 10, 622-628.	0.8	4
192	Improving Hospital Discharge Arrangements for People who are Homeless: The Role of Specialist Integrated Care. <i>International Journal of Integrated Care</i> , 2018, 18, 18.	0.1	4
193	Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2017, 111, 425-432.	0.7	3
194	Genetic variation in <i>FCER1A</i> predicts peginterferon alfa _{2a} -induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1040-1049.	1.0	3
195	Stat2 loss disrupts damage signalling and is protective in acute pancreatitis. <i>Journal of Pathology</i> , 2020, 252, 41-52.	2.1	3
196	Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1152-1158.	0.6	3
197	Spontaneous seroconversion in chronic hepatitis B: role of mutations in the precore/core gene. <i>Digestive Diseases and Sciences</i> , 1998, 43, 1714-1718.	1.1	2
198	Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. <i>Clinical Medicine</i> , 2011, 11, 184-189.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Triple combination treatment for chronic hepatitis C with Protease Inhibitors, pegylated interferon and ribavirin: "Lead-in" or no lead-in? Liver International, 2012, 32, 61-63.	1.9	2
200	Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified. BMJ, The, 2015, 350, h998-h998.	3.0	2
201	Reply to: "Reply to: Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries" Journal of Hepatology, 2018, 68, 864-866.	1.8	2
202	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS ONE, 2020, 15, e0230893.	1.1	2
203	Management of chronic hepatitis C - time for a change?. Journal of Viral Hepatitis, 2002, 9, 82-83.	1.0	1
204	Pegylated interferons. Journal of Drug Evaluation, 2004, 2, 113-127.	0.0	1
205	Corrigendum to "Mechanisms of action of interferon and nucleoside analogues" [J Hepatol 39 (2003) S93-S98]. Journal of Hepatology, 2004, 40, 364.	1.8	1
206	Mutant Ninja viruses. Hepatology, 2015, 61, 421-423.	3.6	1
207	Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Annals of Hepatology, 2016, 15, 333-349.	0.6	1
208	VIRAL LOAD AND NUCLEOTIDE SUBSTITUTIONS IN HEPATITIS B VIRUSES DERIVED FROM CHRONIC HBV PATIENTS. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019046.	0.5	1
209	Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. Value in Health, 2020, 23, 180-190.	0.1	1
210	The A150V Polymorphism of Genotype 3 Hepatitis C Virus Polymerase Inhibits Interferon Alfa by Suppressing Protein Kinase R Activation. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1163-1175.	2.3	1
211	Treatment of Hepatitis C with Interferon: Mechanism of Action of Interferon. , 1994, , 594-600.		1
212	Interferon Proteins: Structure, Production and Purification. , 2006, , 73-83.		0
213	Hepatitis B and C Viruses" How do They Affect Management of IBD?. , 0, , 142-145.		0
214	Other liver viruses. Medicine, 2011, 39, 561-563.	0.2	0
215	Reply to: "Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis" Journal of Hepatology, 2013, 58, 1260.	1.8	0
216	Telaprevir: evidence and guidance for use in clinical practice. Clinical Practice (London, England), 2013, 10, 265-273.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Journal of Viral Hepatitis commencing January 2015. Journal of Viral Hepatitis, 2014, 21, 457-457.	1.0	0
218	Hepatitis C genotype 1. Current Opinion in Infectious Diseases, 2014, 27, 535-539.	1.3	0
219	Hepatitis C triple therapy in the near future: New opportunities to cure. Journal of Hepatology, 2014, 61, 1192.	1.8	0
220	Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. Journal of Viral Hepatitis, 2016, 23, 227-231.	1.0	0
221	The Journal Of Viral Hepatitis 2016. Journal of Viral Hepatitis, 2016, 23, 4-4.	1.0	0
222	Reply to: "High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme" Journal of Hepatology, 2016, 65, 448.	1.8	0
223	Editorial for "Supplement on Optimal Therapy for Chronic Hepatitis B in China" Journal of Viral Hepatitis, 2017, 24, 3-3.	1.0	0
224	IDDF2018-ABS-0113...The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis. , 2018, , .		0
225	Targeted vs opportunistic screening for viral hepatitis among UK migrant communities: a cost-effectiveness analysis. British Journal of Health Care Management, 2021, 27, 90-98.	0.1	0
226	Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation). World Scientific Series in 20th Century Biology, 2000, , 552-556.	0.1	0
227	HBeAg-Negative Chronic Hepatitis B Infection with Abnormal Transaminases and Minimal Changes on Liver Biopsy. , 0, , 135-137.		0
228	Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use itab initio or Sequentially?. , 0, , 138-141.		0
229	Hepatitis B Infection in Surgeons and Healthcare Workers: What should we do to Protect Patients?. , 0, , 151-153.		0
230	Novel Interferons: Is there Life in the Old Dog Yet?. , 0, , 236-238.		0
231	Most Patients with Hepatitis C will Die from their Disease. , 0, , 246-248.		0